Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia:: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

被引：2535

作者：

Hallek, Michael ^{[1
]}

Cheson, Bruce D. ^{[2
]}

Catovsky, Daniel ^{[3
]}

Caligaris-Cappio, Federico ^{[4
]}

Dighiero, Guillaume ^{[5
]}

Doehner, Hartmut ^{[6
]}

Hillmen, Peter ^{[7
]}

Keating, Michael J. ^{[8
]}

Montserrat, Emili ^{[9
]}

Rai, Kanti R. ^{[10
]}

Kipps, Thomas J. ^{[11
]}

机构：

[1] Univ Cologne, Innere Med Klin 1, D-50924 Cologne, Germany

[2] Georgetown Univ Hosp, Lombardi Canc Ctr, Washington, DC 20007 USA

[3] Inst Canc Res, London SW3 6JB, England

[4] Univ Vita Salute, Ist Ricovero & Cura Carattere Sci IRCSS San Raffa, Milan, Italy

[5] Inst Pasteur, Montevideo, Uruguay

[6] Univ Ulm, Ulm, Germany

[7] Pinderfields Gen Hosp, Wakefield, England

[8] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[9] Hosp Clin Barcelona, Barcelona, Spain

[10] Long Isl Jewish Med Ctr, Div Hematol Oncol, New Hyde Pk, NY 11042 USA

[11] Univ Calif San Diego, Rebecca & John Moores Canc Ctr, La Jolla, CA 92093 USA

来源：

BLOOD | 2008年 / 111卷 / 12期

关键词：

D O I：

10.1182/blood-2007-06-093906

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Standardized criteria for diagnosis and response assessment are needed to interpret and compare clinical trials and for approval of new therapeutic agents by regulatory agencies. Therefore, a National Cancer Institute-sponsored Working Group (NCI-WG) on chronic lymphocytic leukemia (CLL) published guidelines for the design and conduct of clinical trials for patients with CLL in 1988, which were updated in 1996. During the past decade, considerable progress has been achieved in defining new prognostic markers, diagnostic parameters, and treatment options. This prompted the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) to provide updated recommendations for the management of CLL in clinical trials and general practice.

引用

页码：5446 / 5456

页数：11

共 75 条

[1]

[Anonymous], 1999, J Natl Cancer Inst, V91, P861

[2]

[Anonymous], COMM TOX CRIT

[3]

[Anonymous], 2001, WHO CLASSIFICATION T

[4]

Balducci L, 2000, Oncologist, V5, P224, DOI 10.1634/theoncologist.5-3-224

[5]

BINET JL, 1981, CANCER-AM CANCER SOC, V48, P198, DOI 10.1002/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO

[6]

2-V

[7] CD38 as a prognostic factor in BCeH chronic lymphocytic leukaemia (B-CLL): Comparison of three approaches to analyze its expression [J].

Boonstra, JG ;

van Lom, K ;

Langerak, AW ;

Graveland, WJ ;

Valk, PJM ;

Kraan, J ;

van 't Veer, MB ;

Gratama, JW .

CYTOMETRY PART B-CLINICAL CYTOMETRY, 2006, 70B (03) :136-141

[8] Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia [J].

Bosch, F ;

Ferrer, A ;

López-Guillermo, A ;

Giné, E ;

Bellosillo, B ;

Villamor, N ;

Colomer, D ;

Cobo, F ;

Perales, M ;

Esteve, J ;

Altés, A ;

Besalduch, J ;

Ribera, JM ;

Montserrat, E .

BRITISH JOURNAL OF HAEMATOLOGY, 2002, 119 (04) :976-984

[9] Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: Justification for risk-adapted therapy [J].

Byrd, JC ;

Gribben, JG ;

Peterson, BL ;

Grever, MR ;

Lozanski, G ;

Lucas, DM ;

Lampson, B ;

Larson, RA ;

Caligiuri, MA ;

Heerema, NA .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (03) :437-443

[10] Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-) [J].

Caballero, D ;

García-Macro, JA ;

Martino, R ;

Mateos, V ;

Ribera, JM ;

Sarrá, J ;

León, A ;

Sanz, G ;

la Serna, JC ;

Cabrera, R ;

González, M ;

Sierra, J ;

San Miguel, J .

CLINICAL CANCER RESEARCH, 2005, 11 (21) :7757-7763

← 1 2 3 4 5 6 7 8 →